Back to search results

AMAZE 3: NNC0487-0111 for Weight Loss and Obstructive Sleep Apnoea

This study, AMAZE 3, is looking at how well the medicine NNC0487-0111 helps people with excess body weight and obstructive sleep apnoea (OSA - when breathing repeatedly stops and starts during sleep) to lose weight and improve their sleep apnoea. You may be able to join if you are 18 or older, have been diagnosed with moderate-to-severe OSA, and have excess body weight. The study aims to see how much body weight changes and how much the apnoea-hypopnoea index (AHI - a measure of sleep apnoea severity) improves over 80 weeks. The study status is currently unclear.

Study design
This is an interventional study planning to enroll 300 participants. You will receive either NNC0487-0111 or a placebo (a treatment with no active medicine) by injection under the skin once a week, with the treatment decided by chance.
What's involved
You will receive weekly injections under the skin for the duration of the study. The primary outcomes are measured from baseline (week 0) to week 80.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes are measured up to 80 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07571005

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Recruiting
PHASE3Ages 18+InterventionalTreatment
Novo Nordisk A/S
~300 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:NNC0487-0111Placebo (matched to NNC0487-0111)

At a glance

Recruiting sites
55 of 80 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relative change in body weight
Measured over From baseline (week 0) to (week 80)
+1 more outcome measured

Conditions

Obesity
Overweight
Obstructive Sleep Apnoea

Explore related trials

ObesityObstructive Sleep ApneaOverweight

Where it's being run

80 sites across 35 states
Poland9
Turkey (Türkiye)8
Spain7
Texas6
Germany6
Taiwan5
Florida3
Jiangsu3

Study leadership

  • Clinical Transparency dept. 2834 · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female (sex at birth)
Age 18 years or above at the time of signing informed consent
Previously diagnosed moderate-to-severe OSA with an AHI ≥ 15, as diagnosed with polysomnography (PSG), home sleep apnoea test (HSAT), or other method that meets local guidelines prior to screening

Exclusion

Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) as measured by the central laboratory at screening
History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records
Any planned or previous surgery within 90 days prior to screening for sleep apnoea, including septoplasty, turbinoplasty, or other ear, nose, and throat surgeries, including tonsillectomy and adenoidectomy
Significant craniofacial abnormalities that may affect breathing at baseline, for example Treacher Collins syndrome and Pierre Robin Sequence
Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonist (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening

What this trial measures

  • Relative change in body weightFrom baseline (week 0) to (week 80)

    Measured as percentage (%) change in body weight.

  • Change in apnoea-hypopnoea index (AHI)From baseline (week 0) to (week 80)

    Measured as events/hour.